• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Abiomed lands new insurance codes for Impella heart pumps

Abiomed lands new insurance codes for Impella heart pumps

September 7, 2012 By MassDevice staff

Abiomed logo

The American Medical Assn. granted medical device maker Abiomed’s (NSDQ:ABMD) 3 new service codes for the Impella percutaneous heart pumps, effective January 2013.

The new Category I Current Procedure Terminology codes cover insertion, repositioning and removal of Impella percutaneous devices, according to a press release.

CPT codes, owned and managed by the AMA, provide physicians, payers and other nodes in the healthcare pipeline with uniform terminology for clinical services. The majority of healthcare insurers use CPT codes, including the Centers for Medicare & Medicaid Services.

That’s more good news for Abiomed, which recently touted positive findings from a head-to-head study comparing its Impella 2.5 heart pump to intra aortic balloon pump support.

The 452-patient trial showed that the next-generation Impella system led to a reduction in adverse events in and out of the hospital as well as a reduction in repeat vascularization when compared to IABP therapy, according to the report published late last month in the journal Circulation.

Earlier this year the medical device giant posted record Q1 sales and 30% year-over-year Impella sales growth, which Abiomed chairman, president & CEO Michael Minogue told investors was a sign that the technology was becoming the new standard of care for percutaneous circulatory support in the U.S.

"The creation of these newly listed CPT codes, coupled with the updated clinical guidelines from November 2011 and recent PROTECT II publication in Circulation, is generating further momentum for Impella platform adoption," Abiomed chairman, president & CEO Michael Minogue said in prepared remarks.

Later this year the
Society for Cardiac Angiography & Interventions, the American College of Cardiology, and the Heart Rhythm Society, all of which had a hand in shaping the new Impella codes, will provide additional details on valuation and payment for the devices, according to a press release.

The Impella 2.5 device is a percutaneous "micro heart pump" with integrated motor and sensors, which the company bills as the world’s smallest heart pump.

Filed Under: Cardiac Implants, News Well Tagged With: Abiomed, American Heart Assn.

More recent news

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy